India's Biological E. Ltd will soon start Phase III trials of its COVID-19 vaccine and plans producing 75 million to 80 million doses a month from August, its managing director told Reuters on Friday. She told Reuters in February that Biological E. was looking to make about 600 million doses of the J&J vaccine annually. J&J said last month it was in talks with India's government to begin a clinical trial of its single-dose shot. It has administered a total of 163 million doses of the AstraZeneca shot and a domestically made one called Covaxin. The country has also received doses of the Sputnik V vaccine from Russia though it has not been launched yet in the country.

Source: Mint May 07, 2021 07:30 UTC